EU approval and labelling information

Colorectal cancer

Avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic(Pertaining to the spread of a disease, usually cancer, from one organ or part to another non-adjacent organ or part) carcinoma(The medical term for a malignant tumour consisting of transformed epithelial cells, but include transformed cells of unknown cell lineage or origin) of the colon or rectum.

Breast cancer

Avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer. Avastin in combination with capecitabine is indicated for first-line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine.

Non-small cell lung cancer

Avastin, in addition to platinum-based chemotherapy, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous(Denoting a surface tissue consisting of a single layer of flat scale-like cells) cell histology.

Renal cell carcinoma

Avastin in combination with interferon(A type of immunotherapy. A natural substance produced in the body in tiny amounts as part of the immune response. It is given in much larger quantities as treatment to boost the immune system and help fight cancer) alfa-2a is indicated for first-line treatment of patients with advanced and/or metastatic renal cell carcinoma.